Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18899181 | Compositions and Methods of Generating Novel amiRNA | September 2024 | April 2025 | Allow | 7 | 0 | 1 | No | No |
| 18782965 | METHOD FOR TREATING C. ACNES BACTERIA-ASSOCIATED DISEASES | July 2024 | May 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18361363 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | July 2023 | May 2024 | Allow | 9 | 1 | 1 | No | No |
| 18334632 | MODULATORS OF HSD17B13 EXPRESSION | June 2023 | September 2023 | Allow | 3 | 1 | 0 | No | No |
| 18069543 | GENETIC MODIFICATION OF MAMMALIAN CELLS TO CONFER RESISTANCE TO CSF1R ANTAGONISTS | December 2022 | May 2025 | Allow | 29 | 3 | 0 | Yes | No |
| 18050760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BETA-CATENIN-ASSOCIATED DISEASE OR DISORDER | October 2022 | March 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17916060 | Double Stranded RNA Specifically Inhibiting Expression of IL-23 and Pharmaceutical Composition Comprising Same | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17818548 | TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR VACCINATION | August 2022 | April 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17849513 | MONOCYTE AND MACROPHAGE BINDING APTAMERS AND THEIR APPLICATION | June 2022 | September 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17834988 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF ALPHA-1 ANTITRYPSIN | June 2022 | August 2024 | Allow | 27 | 2 | 0 | No | No |
| 17663377 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | May 2022 | April 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17697319 | LONG NON-CODING RNA IN CANCER | March 2022 | April 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17671048 | REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING | February 2022 | May 2025 | Allow | 39 | 1 | 1 | No | No |
| 17537005 | EXOSOMES AND MICRO-RIBONUCLEIC ACIDS FOR TISSUE REGENERATION | November 2021 | April 2024 | Allow | 28 | 3 | 1 | No | No |
| 17515938 | MOLECULAR PATHOGENESIS OF MICROCARCINOMA OF THE THYROID | November 2021 | March 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17441895 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | September 2021 | January 2024 | Allow | 27 | 3 | 1 | No | No |
| 17293153 | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE | May 2021 | April 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17289767 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | April 2021 | May 2025 | Allow | 48 | 1 | 2 | No | No |
| 17244835 | METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS | April 2021 | May 2025 | Abandon | 49 | 2 | 1 | No | Yes |
| 17276105 | REDUCING CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS | March 2021 | May 2025 | Allow | 50 | 1 | 1 | No | No |
| 17264727 | METHOD OF IDENTIFYING OR PRODUCING AN APTAMER FOR A DENATURED PEPTIDE OR PROTEIN | January 2021 | October 2024 | Abandon | 45 | 2 | 0 | Yes | No |
| 17156348 | Treatment Of Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, And Liver Fibrosis | January 2021 | December 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17258879 | Compositions and Methods for Treating Endometriosis | January 2021 | December 2024 | Allow | 47 | 4 | 1 | No | No |
| 17121835 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | December 2020 | April 2025 | Allow | 52 | 2 | 1 | No | No |
| 17251200 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | December 2020 | December 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17052945 | EXTRAHEPATIC DELIVERY | November 2020 | October 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16968904 | GENE EDITING USING HOMOLOGY-INDEPENDENT UNIVERSAL GENOME ENGINEERING TECHNOLOGY | August 2020 | February 2025 | Allow | 54 | 2 | 2 | No | No |
| 16647241 | RNA molecules | March 2020 | May 2025 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16371026 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING MICRORNA AS ACTIVE INGREDIENT | March 2019 | February 2020 | Allow | 11 | 1 | 0 | Yes | No |
| 16316378 | COLLAGEN-MIMETIC PEPTIDE MEDIATED DELIVERY OF NUCLEIC ACID CARRIERS FOR EFFICIENT DELIVERY FROM COLLAGEN | January 2019 | August 2024 | Allow | 60 | 3 | 1 | No | No |
| 15878176 | MIR-92 INHIBITORS AND USES THEREOF | January 2018 | December 2018 | Allow | 11 | 0 | 1 | Yes | No |
| 15553097 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING MICRORNA AS ACTIVE INGREDIENT | August 2017 | April 2019 | Allow | 20 | 2 | 1 | Yes | No |
| 15675877 | MIRNAS AS NOVEL THERAPEUTIC ADJUVANTS AND BIOMARKERS FOR THE PROGNOSIS AND TREATMENT OF DRUG RESISTANT BREAST CANCERS | August 2017 | August 2019 | Allow | 24 | 2 | 1 | Yes | No |
| 15514043 | CDC25A INHIBITOR FOR THE TREATMENT OF DRUG RESISTANT CANCER OR FOR THE PREVENTION OF TUMOR RELAPSE | March 2017 | September 2018 | Allow | 17 | 1 | 1 | No | No |
| 14613657 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA | February 2015 | April 2019 | Allow | 51 | 2 | 1 | Yes | Yes |
| 14414393 | COMBINATION THERAPY III | January 2015 | August 2018 | Allow | 43 | 2 | 1 | No | Yes |
| 13941262 | Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals | July 2013 | September 2019 | Allow | 60 | 7 | 1 | Yes | Yes |
| 13876103 | AXL RECEPTOR TYROSINE KINASE APTAMER INHIBITOR FOR USE IN THERAPY | March 2013 | January 2014 | Allow | 10 | 1 | 1 | No | No |
| 13656195 | TREATMENT OF TUMORS WITH GENETICALLY ENGINEERED HERPES VIRUS | October 2012 | March 2014 | Allow | 17 | 1 | 1 | Yes | No |
| 13651123 | RTP801L SIRNA COMPOUNDS AND METHODS OF USE THEREOF | October 2012 | August 2013 | Allow | 10 | 0 | 0 | No | No |
| 13266219 | COMPOSITIONS AND METHODS FOR THERAPY OF MACULAR DEGENERATION | March 2012 | January 2013 | Allow | 15 | 0 | 0 | No | No |
| 13359271 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | January 2012 | July 2013 | Allow | 18 | 1 | 1 | No | No |
| 13301147 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA | November 2011 | April 2013 | Allow | 17 | 2 | 1 | Yes | No |
| 13301204 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA | November 2011 | April 2013 | Allow | 17 | 2 | 1 | Yes | No |
| 13296448 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-29A | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13296291 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-103-2 | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13296500 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-10A | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13296371 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-203 | November 2011 | September 2012 | Allow | 11 | 1 | 0 | Yes | No |
| 13295280 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING LET-7G | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13295209 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-181B | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13295440 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-16B | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13295692 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING MIR-106A | November 2011 | September 2012 | Allow | 10 | 1 | 0 | Yes | No |
| 13059862 | MICRO RNA (MiRNA) AND NEUROFIBROMATOSIS TYPE 1: A ROLE IN DIAGNOSIS AND THERAPY | May 2011 | June 2013 | Allow | 28 | 1 | 1 | No | No |
| 13049011 | PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF | March 2011 | March 2012 | Allow | 12 | 1 | 0 | No | No |
| 13013758 | METHOD USEFUL FOR HCV RNA898 INFECTION. | January 2011 | March 2012 | Allow | 13 | 0 | 1 | No | No |
| 12973681 | METHODS FOR NEUTRALIZING ANTHRAX OR ANTHRAX SPORES | December 2010 | October 2012 | Allow | 22 | 2 | 1 | Yes | No |
| 12811306 | RNA INTERFERENCE FOR THE TREATMENT OF HEART FAILURE | December 2010 | November 2012 | Allow | 29 | 1 | 1 | Yes | No |
| 12921339 | Pharmaceutical Compositions for Treatment of MicroRNA Related Diseases | November 2010 | November 2012 | Allow | 26 | 2 | 2 | No | No |
| 12927144 | SIRNA TARGETING TIE-2 | November 2010 | August 2012 | Allow | 21 | 1 | 1 | No | No |
| 12924225 | APTAMER AND DETECTION METHOD FOR C-REACTIVE PROTEIN | September 2010 | August 2013 | Allow | 35 | 1 | 1 | No | No |
| 12807526 | SIRNA TARGETING PROTO-ONCOGENE MET | September 2010 | March 2012 | Allow | 19 | 0 | 1 | No | No |
| 12806570 | SIRNA TARGETING BETA SECRETASE (BACE) | August 2010 | April 2011 | Allow | 7 | 0 | 1 | No | No |
| 12856954 | COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER | August 2010 | October 2012 | Allow | 26 | 2 | 1 | No | No |
| 12802443 | TREATMENT OF TUMORS WITH GENETICALLY ENGINEERED HERPES VIRUS | June 2010 | July 2012 | Allow | 25 | 2 | 1 | No | No |
| 12774566 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | May 2010 | November 2011 | Allow | 18 | 2 | 0 | Yes | No |
| 12671580 | METHODS FOR REVERTING METHYLATION BY TARGETING METHYLTRANSFERASES | March 2010 | November 2012 | Allow | 33 | 1 | 1 | No | No |
| 12723466 | MULTIPLE PROMOTER EXPRESSION CASSETTES FOR SIMULTANEOUS DELIVERY OF RNAI AGENTS | March 2010 | June 2012 | Allow | 27 | 0 | 0 | No | No |
| 12714264 | VECTOR | February 2010 | September 2011 | Allow | 18 | 1 | 0 | No | No |
| 12703158 | PROTEASE SENSITIVITY EXPRESSION SYSTEM | February 2010 | April 2012 | Allow | 26 | 1 | 1 | No | No |
| 12640148 | SIRNA USEFUL TO SUPPRESS EXPRESSION OF EIF-5A1 | December 2009 | April 2012 | Allow | 28 | 1 | 1 | No | No |
| 12641159 | ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS | December 2009 | July 2013 | Allow | 43 | 2 | 1 | No | No |
| 12653402 | SIRNA TARGETING BETA SECRETASE (BACE) | December 2009 | June 2010 | Allow | 6 | 0 | 1 | No | No |
| 12590097 | SIRNA TARGETING PROTO-ONCOGENE MET | November 2009 | June 2010 | Allow | 7 | 1 | 0 | No | No |
| 12531752 | RNA INTERFERENCE MEDIATED INACTIVATION OF HEPATITIS B VIRUS IN A SUBJECT | September 2009 | March 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12586167 | SIRNA TARGETING TIE-2 | September 2009 | August 2010 | Allow | 11 | 1 | 1 | No | No |
| 12086109 | MICRORNAS THAT REGULATE MUSCLE CELL PROLIFERATION AND DIFFERENTIATION | September 2009 | January 2013 | Allow | 55 | 2 | 1 | No | No |
| 12584705 | SIRNA TARGETING SURVIVIN | September 2009 | June 2010 | Allow | 9 | 1 | 1 | No | No |
| 12555609 | METHOD OF USING GOLD NANORODS-SIRNA COMPLEXES | September 2009 | June 2011 | Allow | 21 | 1 | 1 | No | No |
| 12549110 | TREATMENT OF NEURODEGENERATIVE DISEASE THROUGH INTRACRANIAL DELIVERY OF SIRNA | August 2009 | October 2011 | Allow | 26 | 2 | 1 | No | No |
| 12545774 | HUMAN TELOMERASE CATALYTIC SUBUNIT | August 2009 | April 2012 | Allow | 31 | 1 | 0 | No | No |
| 12471166 | NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE | May 2009 | May 2011 | Allow | 24 | 1 | 1 | No | No |
| 12295960 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDE | March 2009 | January 2012 | Allow | 39 | 1 | 1 | No | No |
| 12400625 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | March 2009 | September 2012 | Allow | 42 | 3 | 1 | Yes | No |
| 12391028 | MICRO-RNAS THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF | February 2009 | March 2011 | Allow | 25 | 1 | 1 | No | No |
| 12388856 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | February 2009 | March 2014 | Allow | 60 | 3 | 2 | No | No |
| 12372899 | TREATING HEPATOMA BY INHIBITING EXPRESSION OF GANKYRIN | February 2009 | December 2010 | Allow | 22 | 2 | 0 | Yes | No |
| 12376940 | METHOD FOR TREATMENT OF HUNTINGTON'S DISEASE THROUGH INTRACRANIAL DELIVERY OF SIRNA | February 2009 | March 2011 | Allow | 25 | 2 | 0 | Yes | No |
| 12346940 | METHOD FOR INHIBITING THE ACTIVITY OF MIR-155 | December 2008 | October 2011 | Allow | 33 | 1 | 1 | No | No |
| 12066903 | METHOD FOR DETERMINING IMMUNOSTIMULATORY ACTIVITY OF RNA OLIGONUCLEOTIDES | November 2008 | August 2011 | Allow | 41 | 1 | 2 | No | No |
| 12092780 | INHIBITION OF AUTOPHAGY GENES IN CANCER CHEMOTHERAPY | October 2008 | August 2011 | Allow | 39 | 1 | 1 | Yes | No |
| 12192356 | PRIMER-EXTENSION BASED METHOD FOR THE GENERATION OF siRNA/miRNA EXPRESSION VECTORS | August 2008 | May 2014 | Allow | 60 | 2 | 1 | No | No |
| 12183354 | COMPOSITIONS AND METHODS FOR INHIBITING CAR GENE EXPRESSION BY RNA INTERFERENCE | July 2008 | June 2010 | Allow | 23 | 1 | 1 | Yes | No |
| 10593597 | MATERIALS AND METHODS FOR TREATMENT OF CANCER | June 2008 | August 2010 | Allow | 47 | 2 | 1 | Yes | No |
| 12081790 | TRANSCRIPTIONAL REPRESSION OF SODIUM-IODIDE SYMPORTER IN THYROID CARCINOMA | April 2008 | June 2012 | Allow | 50 | 2 | 1 | Yes | No |
| 12077504 | NUCLEIC ACIDS ENCODING PRO6308 POLYPEPTIDES AND RELATED VECTORS AND HOST CELLS | March 2008 | June 2010 | Allow | 27 | 2 | 1 | Yes | No |
| 11666001 | TOPICAL ADMINISTRATIONS OF ANTISENSE COMPOUNDS TO VLA-4 FOR THE TREATMENT OF RESPIRATORY CONDITIONS | January 2008 | February 2014 | Allow | 60 | 3 | 1 | No | No |
| 11980263 | SIRNA TARGETING PROTO-ONCOGENE MET | October 2007 | August 2009 | Allow | 21 | 0 | 1 | No | No |
| 11821562 | METHODS OF PROTEIN DESTABILIZATION AND USES THEREOF | June 2007 | June 2010 | Allow | 36 | 1 | 1 | No | No |
| 11719517 | COMPOSITION COMPRISING DOUBLE STRANDED RNA THAT INHIBITS EXPRESSION OF NEU3 AND METHOD FOR TREATING CANCER | May 2007 | May 2010 | Allow | 36 | 1 | 1 | Yes | No |
| 11573269 | INHIBITORS OF L1 AND ADAM10 FOR THE TREATMENT OF CARCINOMAS | May 2007 | March 2011 | Allow | 60 | 1 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANGELL, JON E.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ANGELL, JON E works in Art Unit 1637 and has examined 170 patent applications in our dataset. With an allowance rate of 93.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner ANGELL, JON E's allowance rate of 93.5% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by ANGELL, JON E receive 2.72 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ANGELL, JON E is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +8.3% benefit to allowance rate for applications examined by ANGELL, JON E. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.6% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 44.2% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 78.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 62.7% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.8% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.